NOVATO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the first quarter ended March 31, 2014. “We have continued to make progress with our pipeline of clinical-stage programs for five diseases since the completion of our initial public offering in early 2014,” said Emil D. Kakkis, Ph.D., M.D., Chief Executive Officer and President of Ultragenyx. “We are encouraged by the clinical results from our recombinant human beta-glucuronidase (rhGUS), sialic acid extended-release (SA-ER), and KRN23 programs, as well as the initiation of clinical studies for our triheptanoin programs.” - See more at: http://www.globenewswire.com/news-release/2014/05/12/635409/10081154/en/Ultragenyx-Reports-First-Quarter-2014-Financial-Results-and-Corporate-Update.html#sthash.xEt76mQi.dpuf
Help employers find you! Check out all the jobs and post your resume.
